{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
MannKind Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
MannKind Corp., a small-cap pharmaceutical company, has seen significant stock price fluctuations, currently at $5.31. Despite a challenging year-to-date performance compared to the S&P 500, the company has demonstrated resilience with a notable 5-year return. Technical indicators reflect mixed sentiments, underscoring the need for ongoing evaluation.
MannKind Corp. Forms Golden Cross, Signaling Potential Bullish Breakout
MannKind Corp. has recently achieved a Golden Cross, indicating a potential shift in momentum. Despite a challenging year with a 20.88% decline, the stock has shown resilience, rising today while the S&P 500 dipped. Long-term performance remains strong, with notable gains over three and five years.
MannKind Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
MannKind Corp., a small-cap pharmaceutical company, has seen its stock price slightly decrease to $5.66, following notable volatility over the past year. Despite a recent weekly return of 5.01%, the year-to-date performance reflects an 11.98% decline, contrasting with broader market trends. The company has demonstrated significant resilience over five years.
Is MannKind Corp. technically bullish or bearish?
As of October 3, 2025, MannKind Corp. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 year-to-date and over the past year, but achieving a strong 5-year return of 216.20%.
Is MannKind Corp. technically bullish or bearish?
As of October 3, 2025, MannKind Corp. shows a neutral trend with mixed technical signals, being mildly bearish on monthly indicators but bullish weekly, and has outperformed the S&P 500 recently while underperforming year-to-date.
Is MannKind Corp. technically bullish or bearish?
As of October 3, 2025, MannKind Corp. exhibits a neutral trend with mixed indicators, showing bullish signals in weekly MACD and Bollinger Bands, while underperforming year-to-date despite strong 3- and 5-year performance compared to the S&P 500.
Is MannKind Corp. technically bullish or bearish?
As of September 8, 2025, MannKind Corp. shows a neutral technical trend with mixed indicators, having outperformed the S&P 500 recently but underperformed over the longer term, with year-to-date returns of -12.75% compared to the S&P 500's 12.22%.
Is MannKind Corp. overvalued or undervalued?
As of November 9, 2016, MannKind Corp. is classified as risky and overvalued, with a P/E ratio of 26, an EV to EBITDA of 13.61, and a PEG ratio of 0.06, significantly higher than its peers, despite a strong 5-year return of 169.71% that has recently underperformed the S&P 500.
Is MannKind Corp. overvalued or undervalued?
As of November 9, 2016, MannKind Corp. is considered risky and overvalued with a P/E ratio of 26 and an EV to EBITDA of 13.61, significantly higher than peers like Catalyst Pharmaceuticals, which has a P/E of 14.87, and has underperformed the S&P 500 with a year-to-date return of -40.98%.
Is MannKind Corp. technically bullish or bearish?
As of May 12, 2025, MannKind Corp. is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and Bollinger Bands, along with negative signals from KST and OBV.
Who are in the management team of MannKind Corp.?
As of March 2022, the management team of MannKind Corp. includes Dr. James Shannon (Chairman), Dr. Michael Castagna (CEO), Dr. Sabrina Kay, Mr. Kent Kresa, Mr. Ronald Consiglio, Dr. Michael Friedman, and Ms. Jennifer Grancio. They oversee the company's strategic direction and operations.
What does MannKind Corp. do?
MannKind Corporation is a biopharmaceutical company that develops inhaled therapies for diabetes and orphan lung diseases. As of March 2025, it reported net sales of $78 million and a net profit of $13 million, with a market cap of approximately $1.14 billion.
How big is MannKind Corp.?
As of Jun 18, MannKind Corp. has a market capitalization of 1,139.75 million, with net sales of 297.60 million and a net profit of 30.12 million over the last four quarters. Shareholder's funds are at -78.82 million, and total assets amount to 393.84 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
